Jade Biosciences, Inc.

About Jade Biosciences, Inc.

Jade Biosciences is an early-stage biotechnology company developing targeted protein degradation therapeutics for oncology and immunology. The company applies its proprietary DELPhe platform, which integrates DNA-encoded libraries with phenotypic screening, to identify small-molecule degraders against previously undruggable targets. Its lead program focuses on novel E3 ligase modulators for hematologic malignancies, supported by venture financing and partnerships. Based in San Diego, California, Jade leverages cross-functional expertise in medicinal chemistry, structural biology, and computational design to advance a pipeline of first-in-class degraders toward clinical development.